These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 27130310

  • 1. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
    Janssens A, Rodeghiero F, Anderson D, Chong BH, Boda Z, Pabinger I, Červinek L, Terrell DR, Wang X, Franklin J.
    Ann Hematol; 2016 Jun; 95(7):1077-87. PubMed ID: 27130310
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
    Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M.
    Blood; 2009 Oct 29; 114(18):3748-56. PubMed ID: 19671919
    [Abstract] [Full Text] [Related]

  • 3. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB, Hsieh L, Buchanan GR, Stine K, Kalpatthi R, Gnarra DJ, Ho RH, Nie K, Eisen M.
    Pediatr Blood Cancer; 2015 Feb 29; 62(2):208-213. PubMed ID: 25345874
    [Abstract] [Full Text] [Related]

  • 4. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I, Escudero-Vilaplana V, Pernía S, Beléndez Bieler C, Fernández-Llamazares CM, Sanjurjo-Sáez M.
    J Clin Pharm Ther; 2014 Aug 29; 39(4):376-82. PubMed ID: 24702274
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
    Rodeghiero F, Stasi R, Giagounidis A, Viallard JF, Godeau B, Pabinger I, Cines D, Liebman H, Wang X, Woodard P.
    Eur J Haematol; 2013 Nov 29; 91(5):423-36. PubMed ID: 23927437
    [Abstract] [Full Text] [Related]

  • 6. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
    Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R.
    Int J Hematol; 2012 Jun 29; 95(6):652-9. PubMed ID: 22532046
    [Abstract] [Full Text] [Related]

  • 7. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ.
    Clin Ther; 2009 Sep 29; 31(9):1887-907. PubMed ID: 19843480
    [Abstract] [Full Text] [Related]

  • 8. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia.
    Grainger J, Bussel J, Tarantino M, Cooper N, Beam D, Despotovic J, Maschan A, Wang K, Eisen M, Bowers C.
    Blood Adv; 2023 Feb 14; 7(3):396-405. PubMed ID: 35413092
    [Abstract] [Full Text] [Related]

  • 9. [Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agonist romiplostim in a patient with immune thrombocytopenia].
    Kirito K, Komatsu N.
    Rinsho Ketsueki; 2013 Mar 14; 54(3):295-9. PubMed ID: 23676646
    [Abstract] [Full Text] [Related]

  • 10. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
    Steurer M, Quittet P, Papadaki HA, Selleslag D, Viallard JF, Kaiafa G, Janssens A, Kozak T, Wadenvik H, Schoonen M, Belton L, Kreuzbauer G.
    Eur J Haematol; 2017 Feb 14; 98(2):112-120. PubMed ID: 27557853
    [Abstract] [Full Text] [Related]

  • 11. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
    Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B.
    Blood; 2011 Oct 20; 118(16):4338-45. PubMed ID: 21832276
    [Abstract] [Full Text] [Related]

  • 12. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD, Bussel JB, Blanchette VS, Beam D, Roy J, Despotovic J, Raj A, Carpenter N, Mehta B, Eisen M.
    Haematologica; 2019 Nov 20; 104(11):2283-2291. PubMed ID: 30846500
    [Abstract] [Full Text] [Related]

  • 13. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.
    Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S.
    Br J Haematol; 2013 May 20; 161(3):411-23. PubMed ID: 23432528
    [Abstract] [Full Text] [Related]

  • 14. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP, Heddle NM, Kelton JG, Hamilton K, Wang G, Sholapur N, Carruthers J, Hsia C, Blais N, Toltl L, Hamm C, Pearson MA, Arnold DM.
    Transfusion; 2016 Jan 20; 56(1):73-9. PubMed ID: 26400824
    [Abstract] [Full Text] [Related]

  • 15. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.
    Doobaree IU, Newland A, McDonald V, Nandigam R, Mensah L, Leroy S, Seesaghur A, Patel H, Wetten S, Provan D.
    Eur J Haematol; 2019 May 20; 102(5):416-423. PubMed ID: 30758874
    [Abstract] [Full Text] [Related]

  • 16. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
    Newland A, Godeau B, Priego V, Viallard JF, López Fernández MF, Orejudos A, Eisen M.
    Br J Haematol; 2016 Jan 20; 172(2):262-73. PubMed ID: 26537623
    [Abstract] [Full Text] [Related]

  • 17. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
    Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R.
    Int J Hematol; 2011 Jul 20; 94(1):71-80. PubMed ID: 21706145
    [Abstract] [Full Text] [Related]

  • 18. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
    Al-Samkari H, Van Cott EM, Kuter DJ.
    Ann Hematol; 2019 Mar 20; 98(3):581-588. PubMed ID: 30446804
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study.
    Skopec B, Sninska Z, Tzvetkov N, Ivanushkin V, Björklöf K, Hippenmeyer J, Mihaylov G.
    Hematology; 2021 Dec 20; 26(1):497-502. PubMed ID: 34238136
    [Abstract] [Full Text] [Related]

  • 20. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M.
    Lancet; 2016 Jul 02; 388(10039):45-54. PubMed ID: 27103127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.